^
    Back
    Association details:
    Biomarker:CCND1 expression
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen: (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    ASH 2023
    Title:

    1744 Cyclin D1-Positive Expression Associated with Prognostic Significance and Clinicopathological Characteristics By Paving the Way for Proliferation in Diffuse Large B-Cell Lymphomas

    Published date:
    11/02/2023
    Excerpt:
    In this study, a total of 815 patients diagnosed with DLBCL and treated with R-CHOP or R-CHOP-like regimens...Patients with cyclin D1 expression experienced shorter progression-free survival (PFS) and overall survival (OS) compared to cyclin D1-negative patients (p<0.05)...Cyclin D1-positive DLBCL patients exhibited aggressive clinical behavior and inferior survival outcomes compared to DLBCL patients without cyclin D1 expression.
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    EHA 2022
    Title:

    PREVALENCE AND CLINICAL IMPLICATIONS OF CYCLIN D1 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA

    Published date:
    05/12/2022
    Excerpt:
    The authors reviewed 541 patients who were diagnosed with DLBCL treated with R-CHOP (rituximab with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone ,R-CHOP) in 3 years....patients with cyclin D1-positive DLBCL had shorter PFS and OS than cyclin D1-negative patients (P<0.05).